Acquired
Novo Nordisk (Ozempic)
David Rosenthal
And the thought is that if you could somehow get more GLP-1 into these patients' bodies, you could stabilize their insulin production and thus treat the disease. Seems pretty straightforward. You could imagine that you could now just use the same recombinant DNA techniques to genetically engineer more GLP-1, just like you engineer human insulin. No big deal.
0
💬
0
Comments
Log in to comment.
There are no comments yet.